ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
about
Efficacy of eribulin in breast cancer: a short report on the emerging new data.CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
P2860
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@en
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@nl
type
label
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@en
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@nl
prefLabel
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@en
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@nl
P2093
P2860
P356
P1433
P1476
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
@en
P2093
Hiroto Izumi
Ken-Ichi Ito
Takaaki Oba
P2860
P304
70011-70027
P356
10.18632/ONCOTARGET.11727
P407
P577
2016-08-31T00:00:00Z